Christopher Ryan Sullivan sold $202k of AVTX
Chief Financial Officer at Avalo Therapeutics, Inc.. 12,394 shares at an average of $16.33, traded Sep 16, 2026, filed Sep 18, 2026.
Score components
- +22RoleCFO
- +12Trade size$202k at market
- +5Share of holdings soldSold 24% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001810417-26-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | MOption exercise Common Stock10b5-1 | +12,394 | $9.88 | $122k | 52,294 | 24 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -12,394 | $16.33 | $202k | 39,900 | 24 d ago |
| Sep 16, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,394 | $0.00 | $0 | 83,848 | 24 d ago |
Related signals
Other insiders at Avalo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $179k 10,185 shares | -20% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 31Weak | AVTXsell Avalo Therapeutics, Inc. | Jonathan Goldman director | $163k 11,367 shares | -359% | |
| 23Weak | AVTXbuy Avalo Therapeutics, Inc. | June Sherie Almenoff director | $13k 1,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.